Promising Anti-Mitochondrial Agents for Overcoming Acquired Drug Resistance in Multiple Myeloma

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Multiple myeloma (MM) is an incurable blood cancer characterized by high relapse rates.
• Acquired drug resistance, particularly to proteasome inhibitors (PIs), is a major obstacle to extending patient survival.
• Mitochondrial pathways and metabolic reprogramming are key mechanisms underlying drug resistance in MM cells.

Purpose of the Study:

• To compile and review anti-mitochondrial compounds capable of overcoming drug resistance in multiple myeloma.
• To elucidate the mechanisms by which these compounds restore sensitivity to antimyeloma drugs.

Main Methods:

• Comprehensive literature review of studies investigating drug resistance in multiple myeloma.
• Analysis of compounds targeting mitochondrial pathways and their effects on MM cell death.
• Categorization of compounds based on their mechanisms of action (caspase-dependent and independent).

Main Results:

• MM cells resist PIs by reducing oxidative stress and altering apoptotic signals.
• Several anti-mitochondrial compounds, including 2-methoxyestradiol, Artesunate, and b-AP15, induce cell death via caspase-independent pathways (e.g., increased oxidative stress).
• Other agents like CDDO-Im, FTY720, and GLS1-inhibitors restore PI efficacy through caspase-dependent mechanisms.
• All reviewed compounds demonstrated improved efficacy when used in combination with standard antimyeloma drugs.

Conclusions:

• Targeting mitochondrial pathways presents a promising strategy to overcome drug resistance in multiple myeloma.
• A diverse range of anti-mitochondrial compounds, acting through both caspase-dependent and independent mechanisms, can re-sensitize resistant MM cells.
• Combination therapy with these novel agents and existing drugs holds potential for improving treatment outcomes in relapsed/refractory MM.